Corcept director-linked foundation sells 20K shares

Corcept Therapeutics director David L. Mahoney reported an indirect open-market sale of common stock through The Black Dog Private Foundation.

Rhea-AI Filing Summary

Corcept Therapeutics director David L. Mahoney reported an indirect open-market sale of common stock through The Black Dog Private Foundation. The foundation sold 20,000 shares at a weighted average price of $84.5253 per share, with individual prices ranging from $84.44 to $85.11.

After the sale, the foundation held 26,147 shares of Corcept common stock. A separate indirect holding, the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, is shown with 1,237,145 shares of common stock following the reported transactions.

Insider Trade Summary

Net Seller: 20,000 shares

Net Sell 2 txns

Insider MAHONEY DAVID L

Role Director

Sold 20,000 shs ($1.69M)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,000	$84.5253	$1.69M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 26,147 shares (Indirect, The Black Dog Private Foundation); Common Stock — 1,237,145 shares (Indirect, Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust)

Footnotes (1)

1. F1. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Key Figures

Shares sold: 20,000 shares Weighted average sale price: $84.5253 per share Sale price range: $84.44–$85.11 per share +2 more

5 metrics

Shares sold 20,000 shares Open-market sale of Corcept common stock

Weighted average sale price $84.5253 per share Average price for 20,000 shares sold

Sale price range $84.44–$85.11 per share Range of actual sale prices

Foundation shares after sale 26,147 shares The Black Dog Private Foundation holding after transaction

Family trust holdings 1,237,145 shares David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Key Terms

open-market sale, weighted average sale price, indirect ownership, Form 4

4 terms

open-market sale financial

"The foundation sold 20,000 shares at a weighted average price in an open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

indirect ownership financial

"nature_of_ownership: Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust"

Form 4 regulatory

"reported as a routine Form 4 insider transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Corcept Therapeutics (CORT) report?

Corcept Therapeutics reported an indirect open-market sale of 20,000 common shares linked to director David L. Mahoney. The sale was executed by The Black Dog Private Foundation and is disclosed as a routine Form 4 insider transaction.

At what price were the Corcept Therapeutics (CORT) shares sold?

The 20,000 Corcept shares were sold at a weighted average price of $84.5253 per share. Individual sale prices ranged from $84.44 to $85.11, according to the footnote that accompanies the reported transaction.

How many Corcept Therapeutics (CORT) shares remain with the selling entity?

After selling 20,000 shares, The Black Dog Private Foundation held 26,147 Corcept common shares. This remaining balance reflects the position attributed to that entity following the reported open-market sale transaction on the Form 4.

What other indirect holdings does David L. Mahoney report in Corcept (CORT)?

In addition to the foundation’s holdings, David L. Mahoney reports 1,237,145 Corcept shares indirectly held by the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. This amount reflects the trust’s common stock position following the reported transactions.

Was the Corcept (CORT) insider sale a market transaction?

Yes. The Form 4 describes the 20,000-share disposition as an open-market sale of common stock. The transaction code “S” and related description identify it as a sale in the open market or a private transaction at market-based prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHONEY DAVID L

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S		20,000	D	$84.5253(1)	26,147	I	The Black Dog Private Foundation
Common Stock								1,237,145	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for David L Mahoney	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)